Chen Qi-Fen, Zhang Yi-Wei
Department of Pediatrics, Central Hospital of Jiangjin District, Chongqing 402260, China.
Zhongguo Dang Dai Er Ke Za Zhi. 2018 Feb;20(2):116-120. doi: 10.7499/j.issn.1008-8830.2018.02.007.
To investigate the clinical effect of Saccharomyces boulardii powder combined with azithromycin sequential therapy in the treatment of children with diarrhea secondary to Mycoplasma pneumoniae pneumonia.
A total of 88 children with diarrhea secondary to Mycoplasma pneumoniae pneumonia between June 2015 and March 2017 were divided into control group and study group using a random number table, with 44 children in each group. The children in the control group were given routine treatment combined with azithromycin sequential therapy, and those in the study group were given oral Saccharomyces boulardii powder in addition to the treatment in the control group until the end of azithromycin sequential therapy. After the treatment ended, the two groups were compared in terms of time to improvement of clinical symptoms, length of hospital stay, clinical outcome, defecation frequency before and after treatment, condition of intestinal dysbacteriosis, and incidence of adverse events.
Compared with the control group, the study group had significantly shorter time to improvement of clinical symptoms and length of hospital stay (P<0.05). The study group had a significantly higher response rate than the control group (P<0.05). On days 3 and 5 of treatment, the study group had a significant reduction in defecation frequency compared with the control group (P<0.05). The study group had a significantly lower rate of intestinal dysbacteriosis than the control group (P<0.05). There was no significant difference in the incidence of adverse events between the two groups (P>0.05).
In the treatment of children with diarrhea secondary to Mycoplasma pneumoniae pneumonia, Saccharomyces boulardii powder combined with azithromycin sequential therapy can improve clinical symptoms, shorten the length of hospital stay, reduce defecation frequency and the incidence of intestinal dysbacteriosis, and improve clinical outcomes, and does not increase the risk of adverse events.
探讨布拉氏酵母菌散联合阿奇霉素序贯疗法治疗支原体肺炎继发腹泻患儿的临床效果。
选取2015年6月至2017年3月期间88例支原体肺炎继发腹泻患儿，采用随机数字表法分为对照组和研究组，每组44例。对照组患儿给予常规治疗联合阿奇霉素序贯疗法，研究组患儿在对照组治疗基础上口服布拉氏酵母菌散，至阿奇霉素序贯治疗结束。治疗结束后，比较两组临床症状改善时间､住院时间､临床疗效､治疗前后排便次数､肠道菌群失调情况及不良事件发生率。
与对照组比较，研究组临床症状改善时间及住院时间明显缩短（P<0.05）；研究组总有效率明显高于对照组（P<0.05）；治疗第3、5天，研究组排便次数较对照组明显减少（P<0.05）；研究组肠道菌群失调发生率明显低于对照组（P<0.05）；两组不良事件发生率比较，差异无统计学意义（P>0.05）。
在支原体肺炎继发腹泻患儿治疗中，布拉氏酵母菌散联合阿奇霉素序贯疗法可改善临床症状，缩短住院时间，减少排便次数及肠道菌群失调发生率，提高临床疗效，且不增加不良事件发生风险。
